AI Drug Discovery for Pharma and Biotech

Drug discovery

9

papers

On emerging therapies

Overview

Dubowitz Syndrome is a rare autosomal recessive disorder characterized by microcephaly, short stature, distinctive facial features (e.g., high forehead, micrognathia), and developmental delays. Common systemic manifestations include eczema, immune defects, speech/language deficits, skeletal anomalies, and increased malignancy risk (e.g., leukemia, neuroblastoma). Variability in severity is marked, with some cases linked to LIG4 or NSUN2 mutations and DNA repair defects [1][6][15]. Management requires multidisciplinary care due to multisystem involvement [3][8].

Population

  • Affects <200 individuals globally, with equal gender distribution and diverse ethnic/geographic prevalence [2][6][11].

  • Familial recurrence reported (siblings, twins) suggesting autosomal recessive inheritance [2][6].

Burden

  • High morbidity due to intellectual disability, recurrent infections, and malignancies [6][15][19].

  • Lifelong care coordination required, impacting family and healthcare systems [8][13].

  • Limited prognosis data, with mortality linked to complications (e.g., aplastic anemia, cancer) [6][15].

Therapies

  • Multidisciplinary care: Speech, physical, and occupational therapies; surgical correction of craniofacial/limb anomalies [3][8][13].

  • Medical management: Immunoglobulin therapy for infections, growth hormone supplementation, and dermatological treatment for eczema [3][8][11].

  • Surveillance: Regular hematologic and malignancy screening (e.g., CBC, imaging) [8][13][15].

Categories: rare bone diseases, rare developmental anomalies during embryogenesis, rare genetic diseases, rare neurological diseases, rare ophthalmic disorders, rare skin diseases

Research Papers

9 drug discovery papers about Dubowitz syndrome. Recent publications:

9 drug discovery papers about Dubowitz syndrome. Recent publications:

categories:

Small molecules

proteins
2023-11-07 | Hashimoto Thyroiditis in a Patient With Dubowitz Syndrome and Short Stature

Dubowitz syndrome (DS) is a rare genetic disorder characterized by multiple morphological abnormalities, short stature, and different degrees of mental disability. Endocrinological evaluation should be done for these subjects, as they can suffer from multiple hormonal derangements. We present a case of a 12-year-old Lebanese girl, diagnosed with Dubowitz syndrome, who presented to our clinic for short stature. She had received growth hormones (GHs) and improved her height. More investigations showed the presence of Hashimoto thyroiditis with normal thyroid stimulating hormone, so hormonal follow-up was recommended. The association between Dubowitz syndrome and Hashimoto thyroiditis has not been described so far. Thus, in the setting of this syndrome, it is worthwhile to check for growth hormone deficiency and Hashimoto's thyroiditis.

Open article ↗



1996-06-01 | Growth hormone deficiency in Dubowitz syndrome

Severe short stature as a result of intra-uterine growth retardation is one of the characteristics of Dubowitz syndrome. There have been few reports elaborating growth hormone secretory status in this syndrome. A child with Dubowitz syndrome, who was found to have complete growth hormone (GH) deficiency and who responded to growth hormone therapy, is described. This appears to be the first documentation of GH deficiency in this syndrome.

Open article ↗



small molecules
2023-04-10 | Pyoderma gangrenosum in a patient with Dubowitz syndrome: a new comorbidity?

Dubowitz syndrome is a rare genetic disease with only a few cases reported in the literature. It is characterized by growth retardation, microcephaly, facial dysmorphism and higher risk of developing cancer and cardiomyopathies. PG is an autoinflammatory disorder that causes painful ulcers to develop on the skin and has not been previously associated with Dubowitz syndrome. The authors report the case of a 50-year-old female with Dubowitz syndrome who developed painful ulcerative lesions. An incisional biopsy was performed to rule out other diagnoses, and a subsequent clinical diagnosis of PG was made. The patient was treated with specialized wound dressings and oral glucocorticoids. The clinical picture improved consistently after 7 weeks of therapy. This case report, to the authors' knowledge, is the first to suggest a possible association between Dubowitz syndrome and PG and also to indicate an effective treatment.

Open article ↗



proteins
2023-11-07 | Hashimoto Thyroiditis in a Patient With Dubowitz Syndrome and Short Stature

Dubowitz syndrome (DS) is a rare genetic disorder characterized by multiple morphological abnormalities, short stature, and different degrees of mental disability. Endocrinological evaluation should be done for these subjects, as they can suffer from multiple hormonal derangements. We present a case of a 12-year-old Lebanese girl, diagnosed with Dubowitz syndrome, who presented to our clinic for short stature. She had received growth hormones (GHs) and improved her height. More investigations showed the presence of Hashimoto thyroiditis with normal thyroid stimulating hormone, so hormonal follow-up was recommended. The association between Dubowitz syndrome and Hashimoto thyroiditis has not been described so far. Thus, in the setting of this syndrome, it is worthwhile to check for growth hormone deficiency and Hashimoto's thyroiditis.

Open article ↗



1996-06-01 | Growth hormone deficiency in Dubowitz syndrome

Severe short stature as a result of intra-uterine growth retardation is one of the characteristics of Dubowitz syndrome. There have been few reports elaborating growth hormone secretory status in this syndrome. A child with Dubowitz syndrome, who was found to have complete growth hormone (GH) deficiency and who responded to growth hormone therapy, is described. This appears to be the first documentation of GH deficiency in this syndrome.

Open article ↗



small molecules
2023-04-10 | Pyoderma gangrenosum in a patient with Dubowitz syndrome: a new comorbidity?

Dubowitz syndrome is a rare genetic disease with only a few cases reported in the literature. It is characterized by growth retardation, microcephaly, facial dysmorphism and higher risk of developing cancer and cardiomyopathies. PG is an autoinflammatory disorder that causes painful ulcers to develop on the skin and has not been previously associated with Dubowitz syndrome. The authors report the case of a 50-year-old female with Dubowitz syndrome who developed painful ulcerative lesions. An incisional biopsy was performed to rule out other diagnoses, and a subsequent clinical diagnosis of PG was made. The patient was treated with specialized wound dressings and oral glucocorticoids. The clinical picture improved consistently after 7 weeks of therapy. This case report, to the authors' knowledge, is the first to suggest a possible association between Dubowitz syndrome and PG and also to indicate an effective treatment.

Open article ↗



Access all drug discovery papers and probability of success in trials forecasts:

Access all drug discovery papers and probability of success in trials forecasts:

Drug Discovery Landscape

0 orphan drug designations.

0 orphan drug designations.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.